Aptose Bioscienc SEC Filings

Aptose Biosciences Inc. is the issuer named in this Schedule 13G/A amendment reporting that Bleichroeder LP, Bleichroeder Holdings LLC and Andrew Gundlach beneficially own 41,666 common shares, representing 1.61% of the outstanding common stock (CUSIP 03835T309). The filing shows the reporting persons have sole voting and sole dispositive power over the 41,666 shares and states the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control. The filing identifies Bleichroeder LP as an investment adviser registered under Section 203 and notes clients retain the right to dividends or sale proceeds. Signatures are dated 08/12/2025.

Aptose Biosciences Inc. disclosed in a Form 8-K that on August 13, 2025 it issued a press release reporting its results of operations and financial condition, which is furnished as Exhibit 99.1. The filing states the press release is furnished under General Instruction B.2 and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except where expressly stated. The Form 8-K also provides a cover page interactive XBRL file as Exhibit 104. The report is signed by William G. Rice, Ph.D., Chairman, President and Chief Executive Officer.

Aptose Biosciences reported a six-month net loss of $12.6 million and held $1.298 million of cash, cash equivalents and restricted cash as of June 30, 2025. Total liabilities were $19.962 million and the company reported negative shareholders' equity of $14.4 million and an accumulated deficit of $553.6 million, with current liabilities exceeding current assets by $5.7 million. Management explicitly states substantial doubt about the company’s ability to continue as a going concern and plans to seek additional financing.

On the clinical front, the company is advancing tuspetinib in a Phase 1/2 TUSCANY trial. Ten newly diagnosed AML patients were dosed across 40 mg, 80 mg and 120 mg cohorts with complete remissions (CRs) and MRD-negativity reported at the 40 mg cohort and composite CRs reported at 80 mg and 120 mg; no dose-limiting toxicities were observed and escalation to 160 mg was announced. The company paused further development spending on luxeptinib to prioritize tuspetinib. Related-party financing with Hanmi includes a $10.0 million loan, a debt conversion of $1.538 million into 409,063 shares, and a facility up to $8.5 million with $5.6 million of advances disclosed as subsequent events.

Filing date: August 6, 2025. Aptose Biosciences, Inc. (APTO) filed a Form 8-K reporting a Regulation FD disclosure announcing a press release dated August 6, 2025, which is attached as Exhibit 99.1.

Regulatory note: The press release attached as Exhibit 99.1 is explicitly stated to not be deemed "filed" for purposes of Section 18 of the Exchange Act pursuant to General Instruction B.2. Item 9.01 lists Exhibit 99.1 (Press Release dated August 6, 2025) and Exhibit 104 (Cover Page Interactive Data File).

Company details: Commission File No. 001-32001; EIN 98-1136802; principal executive office at 66 Wellington Street West, Suite 5300, TD Bank Tower, Box 48, Toronto, Ontario M5K 1E6, Canada; phone (647) 479-9828. No securities are registered under Section 12(b). The form is signed by William G. Rice, Ph.D., Chairman, President, and Chief Executive Officer, dated August 6, 2025.

Nasdaq Stock Market LLC has submitted Form 25 to the SEC to remove Aptose Biosciences Inc. (APTO) common shares from listing and registration under Section 12(b) of the Exchange Act. The filing, dated 21 July 2025, states that both the exchange and the issuer have complied with the relevant provisions of 17 CFR 240.12d2-2 for striking or voluntarily withdrawing the securities. The notification is signed on Nasdaq’s behalf by Hearings Advisor Aravind Menon. No financial metrics, reasons for delisting, or additional corporate actions are disclosed in the document.